Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT02798211
- Phase
- PHASE4
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Secukinumab 300 mg — DRUG150 mg x 2 s.c. injection
- Secukinumab 150 mg — DRUG150 mg s.c. injection
- Placebo — OTHERPlacebo
Study Details
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
Key Dates
- Start date
- Jun 27, 2016
- Status verified
- Oct 2021
- Primary completion
- Dec 5, 2018
- Completion
- Dec 5, 2018
Study Design
- Enrollment
- 258 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Group 1secukinumab 300mg s.c. injection
- Active Comparator: Group 2secukinumab 150 mg s.c. injection
- Placebo Comparator: Group 3Placebo s.c. injection
Primary Outcome Measure
Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16 [ Time Frame: 16 Weeks ]
Locations (57)
Find similar trials in Birmingham, AL
By condition
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsRecruiting · M.D. Anderson Cancer Center · Houston, Texas
- Stronger Together Psoriatic Arthritis Wellness StudyRecruiting · Global Healthy Living Foundation · Upper Nyack, New York